Recent research in multiple myeloma emphasizes the importance of combining cytogenetic risk stratification with minimal residual disease status to improve treatment outcomes. This approach involves analyzing genetic changes in cancer cells and determining the amount of disease remaining after treatment. By understanding these factors, healthcare providers can tailor treatment plans more effectively.
This personalized approach can lead to better therapeutic outcomes and prognosis for multiple myeloma patients. It allows for more precise management of the disease based on individual risk factors and response to treatment. The study highlights the role of genetic analysis and disease monitoring in optimizing patient care, contributing to ongoing efforts to refine treatment strategies (Mao et al., 2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar 